Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to assess the safety and effectiveness of combination therapy with zanubrutinib, obinutuzumab, and venetoclax in patients newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).
The purpose of this research study is to understand more about smoldering multiple myeloma (SMM). SMM is multiple myeloma that is not yet causing symptoms. It is usually not treated unless it causes symptoms.
Researchers in this study are exploring the feasibility of making an immunotherapy in a laboratory using white blood cells (called lymphocytes or T cells) collected from the tumor of a patient with metastatic uveal melanoma. This is called autologous tumor-infiltrating lymphocyte (TIL) therapy. The TIL therapy being assessed in this study is called LN-144, and it is designed to activate white blood cells to attack the tumor.
Liver stereotactic ablative radiotherapy (L-SABR) is a standard treatment that uses radiation therapy to target tumors that have spread to the liver while limiting the radiation dose to surrounding organs. L-SABR may also boost the immune response.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are assessing tepotinib with or without ramucirumab in people with non-small cell lung cancer (NSCLC). The people in this study have NSCLC that has metastasized (spread) or recurred (came back) after treatment. Their cancers also have a genetic change called the MET exon 14 skipping mutation.
Researchers are seeing how well the drug FORE8394 works in people with advanced solid tumors, including brain tumors. The people in this study include adults and children with cancers that keep growing or came back even with treatment. Their tumors have mutations (changes or variants) in the BRAF gene.
The purpose of this study is to see how well avutometinib and defactinib work in people with thyroid cancer. The people in this study have one of these kinds of cancer:
Osimertinib is a standard treatment for metastatic non-small cell lung cancer (NSCLC) that has a change (mutation) in the EGFR gene. Researchers think that adding chemotherapy to osimertinib could make treatment more effective.
Researchers are assessing how well erdafitinib works to treat gliomas that keep growing after treatment. The people in this study have glioma with a normal IDH gene and a fusion of two other genes (FGFR-TACC).
